Virginia Tech Scientists Reverse Chronic Pain in Mice

Scientists at Virginia Tech have successfully reversed chronic pain in mice by blocking a single enzyme pathway, offering hope to millions whose suffering defies current medications.

Neuroscientist Ann Gregus and her team focused on nociplastic pain, the mysterious category that includes fibromyalgia, chronic low back pain, and some migraines. Unlike pain from injury or inflammation, this type arises from changes in how the nervous system itself processes signals, leaving no visible damage to treat.

The researchers used compounds developed at the National Institutes of Health to shut down an enzyme system that produces pain-amplifying molecules. Once pain behaviors were well established in the mice, the treatment made tactile and cold hypersensitivity vanish and restored grip strength completely.

This marks a crucial shift from previous research. Earlier studies focused on preventing pain before it develops, but Gregus reversed an established pain state, which mirrors what actual patients experience every day.

The breakthrough matters especially for women, who make up 75% of chronic pain patients and whose symptoms are inadequately managed by current drugs. These patients often hear their pain is "all in their heads," but the research reveals a clear biological mechanism that can be targeted.

Why This Inspires

Standard painkillers like NSAIDs work on inflammatory pathways, but they completely miss the enzyme route that Gregus targeted. Her approach doesn't just mask symptoms but could actually block and reverse the underlying cause.

One compound tested is already in Phase II clinical trials for another condition, meaning it has human safety data. That could dramatically shorten the timeline to testing it for chronic pain in people.

The team's next step involves testing the strategy on conditions like chemotherapy-induced neuropathy, which can linger for years after cancer treatment, and diabetic neuropathy, a leading cause of disability worldwide.

For patients who've exhausted every option and still wake up each day with persistent pain, this research represents something they rarely receive: genuine hope for lasting relief.